Children

Despite limited evidence on its effectiveness in children, T-20 (enfuvirtide, Fuzeon) has been approved for use in children aged six years or older at a dose of 2mg/kg twice daily, up to a maximum of 90mg twice daily. This dose results in drug levels similar to those found in adults and is unaffected by age, weight, or developmental stage.1 The safety of T-20 in children and infants below six years of age is yet to be established.

Preliminary research has found that mild to moderate injection site reactions are common amongst children. Fever and wheezing were also reported.2

References

  1. Bellibas SE et al. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 23: 1137-1141, 2004
  2. Church J et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 21: 653-659, 2002
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.